CSGCT Campus Tour – Guangzhou Station: Empowering China's Cell and Gene Therapy Industry through Collaboration

1.Challenges in Early-Stage Project Financing: The majority of global investments in the cell and gene therapy (CGT) sector are directed toward late-stage clinical projects, making it difficult for early-stage projects to secure funding.

2. Investors are cautious about original technologies and products characterized by high risk and long development cycles, preferring instead to back validated, mature technology platforms.

1.High R&D Costs: The average R&D cost per CGT product exceeds $1 billion (including failed projects), which is 3–5 times higher than that of traditional drugs.

2. High Risk of Cash Flow Disruption: Some CGT companies have long faced pressure on their operating cash flows, relying heavily on financing for survival.

1. Reliance on Imported Key Materials: Core materials such as magnetic beads, culture media, and viral vectors depend on imports, posing a risk of supply chain bottlenecks.

2.U.S. Tariff Hikes on China Drive Surge in Import Costs, Escalating Supply Chain Expenses for SMEs

3. Slow Progress in Domestic Substitution: Low Product Qualification Rates and Suboptimal Cost-Effectiveness

4.  Low Recognition of Domestically Produced Equipment, Long Equipment Validation Cycle

1.High Complexity of International Certification: The FDA has extended the review period for Drug Master File (DMF) filings for domestically produced materials to 18 months, while the EMA requires five years of stability data for viral vectors.

2. Differences in Health Insurance Payment Systems: The commercial insurance coverage rate in the United States is 65%, whereas in European countries, the reimbursement rate is less than 40%, with out-of-pocket expenses accounting for as high as 50%–70%.

1.High Pricing: The average price of approved CGT therapies exceeds one million USD; limited insurance reimbursement coverage combined with a narrow patient population makes profitability challenging.

2.Low Accessibility: Out-of-pocket expenses for patients in China exceed 80%, with annual treatment costs surpassing ten times the per capita disposable income of urban residents.

Event Collaboration:

Ms. Chen 18800157211 (WeChat ID same)

Event Registration:

Mr. Yang 15360825131 (WeChat ID same as phone number)